Kane Biotech Stock Insiders
| KNE Stock | CAD 0.04 0.01 33.33% |
Kane Biotech employs about 11 people. The company is managed by 11 executives with a total tenure of roughly 28 years. Management-performance analysis for Kane Biotech gives investors another way to evaluate how leadership is influencing execution, capital allocation, and operating discipline. The practical question is whether leadership is creating repeatable business progress instead of simply managing the narrative around the company.
| Mark AhrensTownsend CEO President CEO |
Kane |
Management Team Effectiveness
The company has return on total asset (ROA) of -52.58 % suggesting that asset deployment is not yet covering its cost of capital. This trails well behind sector averages. Similarly, it shows a return on equity (ROE) of -596.8 %, meaning that equity holders received a negative return on their investment.Kane Biotech has a large amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it may be worth considering to analyze if each of these insiders have been buying or selling the stock in recent months. Kane Biotech has approximately 0% of its outstanding shares held by institutional investors, 43% by insiders, and 57% in public hands.
Holders Distribution
For Kane Biotech, institutional participation can be supportive or destabilizing depending on whether large holders are building conviction or reducing exposure. This matters because getting in early on a sponsorship cycle may help, but getting caught near a large-holder exit can have the opposite effect.
Workforce Comparison
Kane Biotech falls in the second position for number of employees across the peer group. The total workforce of Health Care industry is now estimated at about 56.0. Kane Biotech retains roughly 11.0 in number of employees claiming about 20% of equities under Health Care sector.
Benchmark Summation
Operator |
This analysis covers sixty-one data points across the selected time horizon. Kane Biotech Price Series Summation is a cross summation of Kane Biotech price series and its benchmark/peer.
Notable Stakeholders
Stakeholders matter for Kane Biotech because not every influential participant is a shareholder acting with the same objective or time horizon. Kane Biotech's stakeholders can support or challenge the entity's direction, which is why tracking them can add context around price-sensitive developments.
| Mark AhrensTownsend | President CEO | Profile | |
| Marc Edwards | Interim CEO, Director | Profile | |
| Kevin Cole | President Inc | Profile | |
| Wendy Nachtigall | Director Marketing | Profile | |
| Gregory Schultz | Chief Board | Profile | |
| Lorne Gorber | Investor Relations | Profile | |
| Dena Mehraban | General Inc | Profile | |
| CNeph MSc | Executive Board | Profile | |
| Ray Dupuis | Chief Officer | Profile | |
| Nicole Sendey | Investor Adviser | Profile | |
| Lori Christofalos | Vice Compliance | Profile |
Management Information & Data Sources
Kane Biotech is a micro-cap company. Management effectiveness is reflected in operating results, capital allocation choices, and margin durability. Operating follow-through relative to stated targets helps calibrate management credibility. CEO is Mark AhrensTownsend with 11 employees and 11 reported executives.
This section for Kane Biotech is built from periodic company reporting and market reference feeds, with reporting definitions aligned before display. Values may update on different source schedules. Insider and management fields are mapped from published filings and company disclosures.
This content is curated and reviewed by:
Raphi Shpitalnik - Junior Member of Macroaxis Editorial BoardWorkforce Efficiency and Productivity
Workforce efficiency at Kane Biotech can help investors judge how effectively labor resources are being converted into revenue and profit over time. The business is commonly classified in the Healthcare sector and the Biotechnology industry.
Kane Biotech Manpower Efficiency
Return on Kane Biotech Manpower
| Revenue Per Employee | 189.2K | |
| Revenue Per Executive | 189.2K | |
| Net Income Per Employee | 554.4K | |
| Net Income Per Executive | 554.4K |
Additional Tools for Kane Stock Analysis
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon |